TSCAN THERAPEUTICS IN

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

07 Dec 2023 04:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition

04 Dec 2023 13:05:00 By Nasdaq GlobeNewswire

TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer

04 Dec 2023 04:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years

30 Nov 2023 04:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

09 Nov 2023 04:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

06 Nov 2023 04:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition

02 Nov 2023 06:05:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting

27 Sep 2023 06:06:51 By Nasdaq GlobeNewswire

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

29 Aug 2023 04:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

10 Aug 2023 04:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Transition of Chief Financial Officer

29 Jun 2023 04:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

06 Jun 2023 04:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting

01 Jun 2023 13:10:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Closing of Public Offering

01 Jun 2023 13:05:35 By Nasdaq GlobeNewswire

TScan Therapeutics to Participate in the Jefferies Healthcare Conference

01 Jun 2023 04:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Pricing of $140 Million Public Offering

25 May 2023 21:37:03 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Launch of Proposed Public Offering

25 May 2023 13:06:50 By Nasdaq GlobeNewswire

TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors

24 May 2023 13:13:47 By Nasdaq GlobeNewswire

TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting

17 May 2023 04:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

10 May 2023 04:00:01 By Nasdaq GlobeNewswire